LXRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lexicon Pharmaceuticals Inc (LXRX) is not a strong buy at the moment for a beginner investor with a long-term focus. While there are some positive catalysts, the weak financial performance, lack of strong trading signals, and neutral sentiment from insiders and hedge funds suggest a cautious approach. Holding or waiting for further developments would be more prudent.
The technical indicators are mixed. The MACD is negative and expanding downward, suggesting bearish momentum. RSI is neutral at 48.263, indicating no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 1.646, with key resistance at 1.751 and support at 1.541.
Novo Nordisk's initiation of a Phase 1 study for LX9851 triggered a $10 million milestone payment to Lexicon Pharmaceuticals.
Analysts have raised price targets recently, with H.C. Wainwright increasing its target to $6, citing progress in clinical and regulatory fronts for pilavapadin.
Financial performance is weak, with significant YoY declines in revenue (-79.31%), net income (-54.01%), and EPS (-55.56%) in Q4
No strong trading sentiment from hedge funds or insiders.
Technical indicators show bearish momentum (negative MACD).
In Q4 2025, Lexicon Pharmaceuticals reported a sharp decline in revenue (-79.31% YoY), net income (-54.01% YoY), and EPS (-55.56% YoY). Gross margin also dropped slightly to 96.34%. Overall, the financials indicate significant challenges in growth and profitability.
Analysts are optimistic, with Citi raising the price target to $2.30 and H.C. Wainwright raising it to $6, maintaining Buy ratings. H.C. Wainwright also increased the probability of success for pilavapadin to 30%, citing progress in clinical and regulatory efforts.
